Henrik Olsen

This inventor holds 17 USPTO granted patents and 13 published patent applications, plus 2 CIPO patents and 6 EPO patents. Top assignees: Gliknik Inc., University System of Maryland. Active years: 2014-2025.

USPTO Granted Patents = 17 (Patent Applications = 13)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 6 (Patent Applications = 12)

Average Co-Inventor Count = 2.7

ph-index = 8

Forward Citations = 146(Granted Patents)

Company Filing History:

University System of Maryland

patents

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12337026 - Methods of treating inflammatory disorders with multivalent Fc compounds (2025-06-24),

2. 12195499 - Manufacturing optimization of GL-2045, a multimerizing stradomer (2025-01-14),

3. 12122836 - Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin Fc compositions with enhanced complement binding (2024-10-22),

4. 12084482 - Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions (2024-09-10),

5. 11795193 - Manufacturing optimization of GL-2045, a multimerizing stradomer (2023-10-24),

6. 11331372 - Methods of treating inflammatory disorders with multivalent Fc compounds (2022-05-17),

7. 11155574 - Manufacturing optimization of GL-2045, a multimerizing stradomer (2021-10-26),

8. 11117940 - Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions (2021-09-14),

9. 11034775 - Cysteine-optimized stradomers (2021-06-15),

10. 10941191 - Immunoglobulin constant region Fc receptor binding agents (2021-03-09),

11. 10851154 - Immunoglobulin constant region Fc receptor binding agents (2020-12-01),

12. 10208105 - Immunoglobulin constant region Fc receptor binding agents (2019-02-19),

13. 9926362 - Immunoglobulin constant region Fc receptor binding agents (2018-03-27),

14. 9683044 - Molecules with antigen binding and polyvalent FC gamma receptor binding activity (2017-06-20),

15. 9512210 - Immunoglobulin constant region Fc receptor binding agents (2016-12-06),

Title: Henrik Olsen: Innovator in Inflammatory Disorder Treatments

Introduction

Henrik Olsen is a prominent inventor based in Baltimore, MD (US), known for his significant contributions to the field of medical therapeutics. With a total of 17 patents, he has focused on developing innovative methods for treating inflammatory and autoimmune disorders.

Latest Patents

One of his latest patents is titled "Methods of treating inflammatory disorders with multivalent Fc compounds." This invention provides methods for identifying patients with inflammatory or autoimmune diseases who show inadequate responses to multi-Fc therapeutics. It also determines the optimal dosage of these therapeutics based on the patient's circulating levels of inactivated C3b (iC3b) and other complement components. Another notable patent is "Manufacturing optimization of GL-2045, a multimerizing stradomer." This disclosure involves optimized methods for producing biologically active proteins known as optimally manufactured stradomers, which are useful in treating autoimmune, inflammatory, and infectious diseases.

Career Highlights

Henrik has worked with notable organizations such as Gliknik Inc. and the University System of Maryland. His work has significantly advanced the understanding and treatment of complex medical conditions.

Collaborations

Henrik has collaborated with esteemed colleagues, including David S Block and Scott E Strome, contributing to the development of innovative therapeutic solutions.

Conclusion

Henrik Olsen's work exemplifies the impact of innovation in the medical field, particularly in treating inflammatory disorders. His patents and collaborations continue to pave the way for advancements in therapeutic methods.